DNA methylation changes in prostate cancer: current developments and future clinical implementation.
about
The mitochondrial side of epigeneticsMolecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue.Novel targeted therapeutics for metastatic castration-resistant prostate cancer.Promoter Methylation in Prostate Cancer and its Application for the Early Detection of Prostate Cancer Using Serum and Urine Samples.Prognostic Value of Promoter Hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in Prostate CancerNovel methylation biomarker panel for the early detection of pancreatic cancer.Epigenetics in prostate cancer.Cancer epigenetics: above and beyondDNA methylation of GSTP1 in human prostate tissues: pyrosequencing analysisA biospectroscopic analysis of human prostate tissue obtained from different time periods points to a trans-generational alteration in spectral phenotype.Regulators of gene expression as biomarkers for prostate cancerPyrosequencing Analysis of APC Methylation Level in Human Prostate Tissues: A Molecular Marker for Prostate Cancer.Methylation of the RARB gene increases prostate cancer risk in black AmericansConcentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer.DNA methylation as a universal biomarker.Future directions in castrate-resistant prostate cancer therapy.Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation.The epigenetic potentials of dietary polyphenols in prostate cancer management.Urine markers and prostate cancerDLEC1, a 3p tumor suppressor, represses NF-κB signaling and is methylated in prostate cancer.ID4 is frequently downregulated and partially hypermethylated in prostate cancer.Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease.DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer.DNA Methylation and the HOXC6 Paradox in Prostate Cancer.Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.RETRACTED: Dysregulation of cell cycle related genes and microRNAs distinguish the low- from high-risk of prostate cancer.Inverse association of p16 INK4a and p14 ARF methylation of the CDKN2a locus in different Gleason scores of prostate cancer.Clinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study.Alterations in methylation status of immune response genes promoters in cell-free DNA during a hemodialysis procedure.Combined hypermethylation of APC and GSTP1 as a molecular marker for prostate cancer: quantitative pyrosequencing analysis.
P2860
Q28081686-FE04951B-60C1-4CE5-9C91-80B991DED5BBQ31043717-5A959BE3-D34E-41D1-9383-1EFD64674180Q33642278-14E17B7C-C328-491C-B5FE-29D2DAFA2011Q34014559-B11B1D47-B3A1-445E-8FDC-A08A7F9B28D1Q34324983-C2F6277F-1D1F-4277-BD85-D94314F90C66Q34374959-C01BA0F5-260E-490A-9552-291EC171A4ACQ35608952-40DAFE4C-CA8B-469D-B83F-CD73FAB88FB9Q35844494-BE733016-102D-4C37-A7DC-8553C00D26B5Q35852010-8A7DEEB8-D3D3-41FE-99AE-AC15F67FFD7CQ35999452-E45C2507-9DB5-441D-9AB3-C198BF7D2737Q36439912-B180175A-838E-4FE9-83FF-12639F352C67Q36705589-00A607E8-731A-4DF2-8526-B9CF30991A90Q37187963-7E6A4E38-35C9-4BC1-9CD5-049466407B4BQ37306747-935B2B98-06ED-42C5-AE4E-C4A28F3AA5CFQ37750858-E22BF3FF-18C0-47D8-86A7-5BF346867849Q37826274-34017FD7-A8F4-4DBA-B582-396EF8436EADQ37876194-BCD9FE47-4A5A-4C12-866D-FB8A6E7DF081Q37988364-A761293D-226F-4EC5-A97A-D31B58F7E238Q38161941-3CF7F87C-595A-407B-B853-A56B21D8DF91Q38191924-4E422407-2D35-4B65-A215-94C244DF5B57Q38913306-3222FB74-0A4C-4F25-8800-DBFB95E0D833Q39481269-A575C7B1-8332-43C1-814D-C81B5103FC90Q40296266-606FEE77-E263-4A9F-AD8C-0F86FE01A05DQ40848507-DED88EEF-4C8E-4A21-BFAA-4B0F24F21D1CQ42585509-1D9E1DB5-0BDE-4DD8-926A-D2842C38DD1CQ42651317-5851BDCC-13D2-4BE9-884E-9FB005CEA6A6Q42969500-44D49AA8-0736-492E-A855-0A6B7F7BF93FQ44285666-30FAF3C8-6A99-4F11-A243-012D9D9FA78DQ47119316-C441C9A1-DFEF-40FB-8EA2-026DB86F5BCAQ47899514-C095E72D-F57A-4125-A8E5-CEE79BF2A6A2Q50950930-582CF9AD-3D0F-4583-A9FD-FC01457CF0C4
P2860
DNA methylation changes in prostate cancer: current developments and future clinical implementation.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
DNA methylation changes in pro ...... uture clinical implementation.
@ast
DNA methylation changes in pro ...... uture clinical implementation.
@en
type
label
DNA methylation changes in pro ...... uture clinical implementation.
@ast
DNA methylation changes in pro ...... uture clinical implementation.
@en
prefLabel
DNA methylation changes in pro ...... uture clinical implementation.
@ast
DNA methylation changes in pro ...... uture clinical implementation.
@en
P2860
P356
P1476
DNA methylation changes in pro ...... uture clinical implementation.
@en
P2093
Mohammad Obaidul Hoque
P2860
P304
P356
10.1586/ERM.09.10
P577
2009-04-01T00:00:00Z